Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nemtabrutinib · ARQ-531, MK-1026

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Merck &

Phase 3 Most advanced trial
MRK Developer
1 Registered trials

What is Nemtabrutinib?

Nemtabrutinib is an orally available, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), including the wild-type enzyme and the C481S resistance mutant. It blocks B-cell receptor signaling and is studied in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ARQ-531, MK-1026
Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK)
Mechanism
Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways
B-cell antigen receptor (BCR) signaling, BTK-mediated survival signaling
Therapy area
Oncology
Developer
Merck & Co. (MRK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
JTZ51LIXN4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06136559 Phase 3 Chronic Lymphocytic Leukemia Recruiting MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CLLLeukemia, Chronic LymphocyticLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small LymphocyticSLLSmall-Cell Lymphoma

Other drugs acting on BTK

More from Merck &

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Nemtabrutinib

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.